CYTK Cytokinetics Incorporated

10.79
+0.32  (+3%)
Previous Close 10.47
Open 10.53
Price To Book 179.83
Market Cap 622812676
Shares 57,721,286
Volume 555,686
Short Ratio
Av. Daily Volume 622,804

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data presented at AAN, May 5, 2019, failed to meet primary endpoint.
Reldesemtiv (CK-2127107) - FORTITUDE-ALS
Amyotrophic lateral sclerosis (ALS)
Phase 1b interim analysis noted lack of efficacy.
CK-2127107
Limited mobility
Phase 3 enrolment to be completed 2Q 2019.
Omecamtiv mecarbil GALACTIC-HF
Acute heart failure
Phase 3 data released November 21, 2017 - primary endpoint not met.
Tirasemtiv - VITALITY
Amyotrophic lateral sclerosis (ALS)
Phase 2 data did not meet endpoints - October 5, 2018.
Reldesemtiv (CK-2127107)
Chronic obstructive pulmonary disease (COPD)
Second Phase 3 trial initiation announced February 21, 2019.
Omecamtiv mecarbil METEORIC-HF
Acute heart failure
Phase 1 data due 3Q 2019.
CK-3773274
Healthy volunteers (hypertrophic cardiomyopathy (HCM))
Phase 1 trial initiation announced February 20, 2019.
AMG 594
Healthy volunteers

Latest News

  1. Edited Transcript of CYTK earnings conference call or presentation 9-May-19 8:30pm GMT
  2. Cytokinetics Inc (CYTK) Q1 2019 Earnings Call Transcript
  3. Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates
  4. Cytokinetics: 1Q Earnings Snapshot
  5. Cytokinetics Reports First Quarter 2019 Financial Results
  6. Cytokinetics to Hold Annual Meeting of Stockholders
  7. Investors scrutinize Peninsula biotech company as Lou Gehrig's disease drug falters
  8. Cytokinetics plunges 19% after Phase 2 trial of ALS drug fails to meet endpoints
  9. Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting
  10. Will Cytokinetics (CYTK) Report Negative Earnings Next Week? What You Should Know
  11. Cytokinetics to Announce First Quarter Results on May 9, 2019
  12. What Are Analysts Expecting From Cytokinetics, Incorporated (NASDAQ:CYTK) In The Next Couple Of Years?
  13. Will Cytokinetics (CYTK) Report Negative Q1 Earnings? What You Should Know
  14. Cytokinetics to Present at April Investor Conferences
  15. New Research Coverage Highlights International Paper, Square, Sealed Air, Calix, e.l.f. Beauty, and Cytokinetics — Consolidated Revenues, Company Growth, and Expectations for 2019
  16. Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL
  17. The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering
  18. Here's Why Cytokinetics Stock Jumped Today
  19. Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
  20. Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis